Verrica completes enrollment in COVE-2 Phase 3 trial; topline due Q1 2027
Verrica Pharmaceuticals said it completed enrollment in COVE-2, its first pivotal Phase 3 trial of YCANTH for common warts. Topline data are expected in Q1 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Verrica Pharmaceuticals completes enrollment in COVE-2 Phase 3 trial
Verrica Pharmaceuticals (VRCA) completed enrollment in the first pivotal Phase 3 trial (COVE-2) of YCANTH for common warts; topline data expected Q1 2027.